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Introduction
Inflammatory bowel disease (IBD) consists of Crohn’s disease (CD) and ulcerative colitis 
(UC). Crohn’s disease is a multisystem disorder with specific clinical and pathological 
features characterised by focal, asymmetrical, transmural, and occasionally granulomatous 
inflammation, primarily affecting the gastro-intestinal tract. Ulcerative colitis, on the 
other hand, is a disease with a predilection for the rectum and colon with continuous 
and superficial inflammation of the colonic mucosa. In the past, the two diseases were 
considered rare in the Chinese population. Recent data, however, show that for unknown 
reasons they are increasing in our locality.1,2 
 There has been a paucity of studies on the management of IBD from the Asia-Pacific 
region including Hong Kong, especially on the use of biologics.3-7 Most of the efficacy and 
safety data about these novel agents have been obtained in western studies. However, it 
has been suggested that genetic susceptibilities in Asian IBD patients differ from those in 
Caucasians.8 Previous studies also reported ethnic differences in the clinical phenotypes 
and complications of these disorders.9 It is therefore likely that the efficacy and side-
effects of biologics in Asians and Caucasians may differ, which suggests that standard 
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 Objective With the increasing use of biologics in patients with inflammatory 
bowel disease, the Hong Kong IBD Society developed a set of 
consensus statements intended to serve as local recommendations 
for clinicians about the appropriate use of biologics for treating 
inflammatory bowel disease.
 Participants The consensus meeting was held on 9 July 2011 in Hong Kong. 
Draft consensus statements were developed by core members of 
the Hong Kong IBD Society, including local gastroenterologists 
and colorectal surgeons experienced in managing patients with 
inflammatory bowel disease.
 Evidence Published literature and conference proceedings on the use 
of biologics in management of inflammatory bowel disease, 
and guidelines and consensus issued by different international 
and regional societies on recommendations for biologics in 
inflammatory bowel disease patients were reviewed.
 Consensus process Four core members of the consensus group drafted 19 
consensus statements through the modified Delphi process. The 
statements were first circulated among a clinical expert panel 
of 15 members for review and comments, and were finalised at 
the consensus meeting through a voting session. A consensus 
statement was accepted if at least 80% of the participants voted 
“accepted completely” or “accepted with some reservation”.
 Conclusions Nineteen consensus statements about inflammatory bowel 
disease were generated by the clinical expert panel meeting. 
The statements were divided into four parts which covered: 
(1) epidemiology of the disease in Hong Kong; (2) treatment of 
the disease with biologics; (3) screening and contra-indications 
pertaining to biologics; and (4) patient monitoring after use of 
biologics. The current statements are the first to describe the 
appropriate use of biologics in the management of inflammatory 
bowel disease in Hong Kong, with an aim to provide guidance 
for local clinical practice.
for the Hong Kong IBD Society
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 目的 隨着使用生物製劑治療炎症性腸病日益普遍，《香港
炎症性腸病學會》制定了一套有關正確使用生物製劑
治療炎症性腸病的共識聲明，為本地醫生提供建議作
參考用。
 參與者 於2011年7月9日舉行共識會議。由《香港炎症性腸
病學會》的主要成員草擬共識聲明，成員包括對於處
理炎症性腸病甚具經驗的胃腸學醫生及結直腸外科醫
生。
 證據 搜尋關於使用生物製劑治療炎症性腸病的文獻及會議
論文撮要，以及國際及地區性學會發出有關的建議和
指引。
 綜述過程 《香港炎症性腸病學會》的四位主要成員於會議前
透過修正式德菲法（Delphi process）草擬了19項共
識，並將草稿給予15位臨床專家小組成員傳閱及徵求
意見，最後通過投票制定了共識聲明的最終版本。每
項聲明均須符合最少八成的小組成員「完全贊成」或
「雖有保留但仍贊成」才可被接納。
 結論 臨床專家小組成員發出了19項的共識。共識聲明分為
以下四部份：炎症性腸病的流行病學、炎症性腸病的
生物製劑治療、與生物製劑有關的篩選及禁忌、和使
用生物製劑後對病人的監察。這份共識聲明首次為本
地醫生提供有關正確使用生物製劑治療炎症性腸病的
建議作參考指引之用。
香港生物製劑治療炎症性腸病的共識聲明
therapies/treatment guidelines for IBD patients in 
western countries may not be applicable to Asian 
counterparts. Owing to the increasing patient load 
and availability of biologics, clinicians should become 
updated on their appropriate use in treating patients 
with IBD, especially from a local perspective. 
 For this reason, the Hong Kong IBD Society 
organised a consensus meeting with the goal of 
developing a set of consensus statements offering 
guidance on the appropriate use of biologics in 
managing IBD patients in Hong Kong. 
Methods
The consensus meeting was held on 9 July 2011 in 
Hong Kong. Members of the Hong Kong IBD Society 
including local gastroenterologists and colorectal 
surgeons experienced in managing affected patients 
were invited. Prior to the meeting, four core members 
of the consensus group drafted 19 consensus 
statements through the modified Delphi process,10 
which were circulated to all participants for review 
and comments. The statements were divided into 
four parts which covered: (1) epidemiology of IBD in 
Hong Kong; (2) treatment of IBD with biologics; (3) 
screening and contra-indications of biologics; and (4) 
monitoring after use of biologics. 
 During the meeting, core members of the 
consensus group reviewed and summarised the 
literature on these four topics. After the presentation, 
panel members (consisting of 15 local clinical experts) 
voted on the statements pertaining to each topic. 
Voting was anonymous. A consensus statement was 
accepted if at least 80% of participants voted “A: accept 
completely” or “B: accept with some reservation” 
(Table). Assessment for each consensus statement 
during the voting session included categorisation 
of evidence and classification of recommendations, 
which were modified from the Canadian Task Force 
on Periodic Health Examination (Table).5 
Results
Epidemiology of inflammatory bowel disease in 
Hong Kong
Statement 1: The incidence of inflammatory bowel 
disease is rising in Hong Kong
Level of agreement: A-73%, B-27%, C-0%, D-0%, E-0%
(Quality of evidence: II-2; Classification of recommendation: B)
Inflammatory bowel disease was once considered 
a rare disease in Hong Kong. However, local 
epidemiologic studies reported a 3-fold increase 
in the incidence of CD and a 6-fold increase in the 
incidence of UC.1,2 The annual incidence of CD and UC 
TABLE.  The grading system for each consensus statement during the voting session
Choice Quality of evidence Classification of recommendation Voting (on recommendation)
A (I) Evidence obtained from at least 1 randomised 
controlled trial
There is good evidence to support the statement Accept completely
B (II-1) Evidence obtained from well-designed control 
trials without randomisation
There is fair evidence to support the statement Accept with some reservation
C (II-2) Evidence obtained from well-designed cohort 
or case-control study
There is poor evidence to support the statement 
but recommendation made on other ground
Accept with major reservation
D (II-3) Evidence obtained from comparison between 
time or places with or without intervention
There is fair evidence to refute the statement Reject with reservation
E (III) Opinion of respected authorities based on 
clinical experience and expert committees
There is good evidence to refute the statement Reject completely
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is estimated to be 1.0 per 100 0001 and 2.1 per 100 000,2 
respectively. The median age at diagnosis of CD 
was 30 years with a male-to-female ratio of 2:1.11 The 
proportions of CD patients with non-stricturing, non-
penetrating (B1), stricturing (B2), and penetrating (B3) 
disease at diagnosis as determined by the Montreal 
classification were 67%, 30%, and 3%, respectively.12 
Half of the patients were diagnosed with ileocolic 
disease (L3) at presentation.11 For UC, the median age 
at diagnosis was 37 years with a male-to-female ratio 
of 1:1.2 The ratio of extensive colitis, left-sided colitis, 
and ulcerative proctitis were 4:3:3.2 
Statement 2: Utilisation of biological therapies in the 
treatment of inflammatory bowel disease needs to be 
optimised in Hong Kong
Level of agreement: A-40%, B-60%, C-0%, D-0%, E-0%
(Quality of evidence: III; Classification of recommendation: C)
In Hong Kong, corticosteroids remain one of the 
most commonly prescribed treatment options for 
IBD patients; 58% of CD and 54% of UC patients 
had taken corticosteroids.13 However, approximately 
one third of them progressed to corticosteroid-
dependent disease after 1 year. Although there 
is accumulating clinical evidence suggesting that 
anti–tumour necrosis factors (anti-TNFs) are highly 
efficacious in the treatment of IBD, their use is limited 
in Asia as compared to western countries. Based on a 
study conducted in a teaching hospital in Hong Kong, 
only 11% of CD patients and 1% of UC patients had 
received anti-TNF therapy.3 A recent survey of current 
IBD patient management in different parts of Asia 
including Hong Kong found that no IBD specialists 
considered anti-TNFs as first-line treatment for 
CD. Only 20% of them considered anti-TNFs as the 
second choice. Less than 15% would choose them 
for the management of UC.4 The limited use of anti-
TNFs in Asia may be due to various factors, including 
high costs, a lack of insurance reimbursement, and 
concern over opportunistic infections.4,5,14 
Statement 3: Current access to biological therapies 
remains limited in Hong Kong mainly due to high cost
Level of agreement: A-40%, B-53%, C-7%, D-0%, E-0%
(Quality of evidence: III; Classification of recommendation: C)
There has been a lack of local cost-utility analyses on 
biologics, but in the panel’s opinion, from a public 
sector perspective the cost of biological agents is 
considered to be high, and so they have to be largely 
self-financed. However, funding is available for those 
who are suffering from moderate-to-severe CD (ie 
CDAI [Crohn’s Disease Activity Index] ≥300, or active 
fistulating disease) and cannot afford the medications. 
Cost remains a major obstacle discouraging patients 
from choosing biological agents as a therapeutic 
option.
Treatment of inflammatory bowel disease with 
biologics
Statement 4: Biologics are effective for the induction 
and maintenance of remission in patients with active 
luminal Crohn’s disease
Level of agreement: A-93%, B-7%, C-0%, D-0%, E-0%
(Quality of evidence: I; Classification of recommendation: A)
Overwhelming data in the literature support the use of 
anti-TNFs (infliximab, adalimumab and certolizumab) 
for patients with luminal CD. The ACCENT I trial (A 
Crohn’s disease Clinical trial Evaluating infliximab in 
a New long-term Treatment regimen I) showed that at 
week 30, patients with moderate-to-severe CD treated 
with infliximab (5 or 10 mg/kg) were more likely to 
sustain clinical remissions than those treated with 
placebo (odds ratio=2.7; 95% confidence interval, 1.6-
4.6).15 In the CHARM (Crohn’s trial of the fully Human 
antibody Adalimumab for Remission Maintenance) 
study, remission rates were significantly higher in 
adalimumab groups (40 mg every other week and 40 
mg weekly) compared to the placebo group at week 
56 (36% and 41% vs 12%, respectively).16 The PRECiSE 
2 (The Pegylated antibody fRagment Evaluation in 
Crohn’s disease: Safety and Efficacy 2) trial showed 
that patients who had responded to 6 weeks of open-
label induction treatment with certolizumab 400 mg 
were more likely to maintain a response at week 
26 when continued on certolizumab pegol than if 
switched to placebo (63% vs 36%).17 Recent data also 
suggest that early use of biologics (ie the top-down 
approach) may be more effective in preventing 
disease progression.18-20 
Statement 5: Biologics should be considered in patients 
with active fistulising Crohn’s disease, particularly in 
those with complex perianal fistulising diseases
Level of agreement: A-80%, B-20%, C-0%, D-0%, E-0%
(Quality of evidence: I; Classification of recommendation: A)
One of the earliest studies on anti-TNFs showed 
that after three doses of infliximab 5 mg/kg, 55% 
of patients with fistulising CD achieved closure of 
draining abdominal or perianal fistulae.21 The pivotal 
ACCENT II maintenance trial also indicated that 
systemic treatment with infliximab 5 mg/kg every 8 
weeks was superior to placebo for closure of draining 
fistulas at week 54 (36% vs 19%).22 Another long-term 
study with infliximab showed that about one third of 
patients had healed fistulae after 5 years of infliximab 
treatment.23 The CHARM study demonstrated that at 
week 56, fistula closure was evident in about one third 
of CD patients receiving adalimumab.16
Statement 6: Biologics are effective for the induction 
of clinical remission in patients with moderately to 
severely active ulcerative colitis who failed treatment 
with corticosteroids and/or immunosuppressants
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Level of agreement: A-53%, B-40%, C-0%, D-7%, E-0%
(Quality of evidence: I; Classification of recommendation: A)
Infliximab has been used in the treatment of patients 
with moderate-to-severe UC who failed conventional 
treatment. In the randomised placebo-controlled 
ACT (the Active ulcerative Colitis Trials) studies, 
patients with moderate-to-severe UC who had failed 
or were intolerant to corticosteroids (ACT-1 and -2) or 
thiopurines (ACT-1) were randomised to infliximab (5 
or 10 mg/kg), or to placebo for 1 year. In the infliximab 5 
mg/kg group, remission (Mayo score ≤2) was achieved 
in 39% (ACT-1) and 34% (ACT-2) at week 8, and 34% 
(ACT-1) and 26% (ACT-2) at week 30, respectively (all 
P≤0.003 compared to placebo).24 In patients with acute 
severe UC refractory to intravenous steroids, a recent 
study showed that infliximab was non-inferior to 
cyclosporin.25 The response rates at day 7 were 84% 
for cyclosporin and 86% for infliximab, respectively. At 
day 98, 10 out of 55 patients treated with cyclosporin 
and 13 out of 56 patients treated with infliximab 
underwent colectomy. 
Statement 7: Recognition of adverse prognostic factors 
should lead to early use of biologics in Crohn’s disease
Level of agreement: A-33%, B-53%, C-13%, D-0%, E-0%
(Quality of evidence: II-1; Classification of recommendation: A)
Severe adverse prognostic factors such as young age, 
presence of perianal lesions, extensive small bowel 
disease, stricturing disease, and deep colonic ulcers 
have been associated with increased risk of colectomy 
and penetrating complications.26 Patients without 
adverse prognostic factors could be considered for 
conventional drugs with rapid step-up to anti-TNF 
agents in those who fail treatment. In patients with 
adverse prognostic factors, anti-TNF therapy with 
or without immunosuppressive drugs should be 
considered early.27 
Statement 8: For maintenance treatment with biologics 
in Crohn’s disease patients, scheduled maintenance 
regimen is superior to episodic regimen
Level of agreement: A-73%, B-20%, C-7%, D-0%, E-0%
(Quality of evidence: I; Classification of recommendation: A)
The ACCENT I trial showed that the scheduled 
maintenance group (infliximab 5 mg/kg at weeks 0, 2, 
and 6 followed by 5 mg/kg or 10 mg/kg every 8 weeks) 
had higher response and remission rates compared 
to those receiving episodic therapy.28 Resorting 
to hospitalisation and surgery also decreased to a 
greater extent in the group scheduled to maintenance 
infliximab group compared to those on episodic 
therapy.29 In a randomised open-label study in 
paediatric CD patients, those receiving scheduled 
infliximab therapy achieved a higher remission rate 
than those receiving episodic therapy (83% vs 61% 
respectively).30 
Statement 9.a: Biologics combined with thiopurine is 
the most effective approach in inducing remission and 
in achieving mucosal healing in Crohn’s disease
Level of agreement: A-80%, B-20%, C-0%, D-0%, E-0%
(Quality of evidence: I; Classification of recommendation: A)
In the recent SONIC (Study Of biologic and 
immunomodulator Naive patients In Crohn’s 
disease) trial, the steroid-free remission rate was 
higher in those on the combination of infliximab 
plus azathioprine compared to the infliximab-alone 
and azathioprine-alone arms. The respective rates 
at week 26 were 57%, 44% and 30%, and at week 50 
they were 72%, 61% and 55%.31 At week 26, mucosal 
healing occurred in 44% of the patients receiving 
combination therapy, as compared to 30% in those 
receiving infliximab alone and 16.5% in those on 
azathioprine alone.31 
Statement 9.b: The risk and benefit of combination 
therapy with biologics and thiopurine should be 
considered in each individual patient
Level of agreement: A-33%, B-53%, C-13%, D-0%, E-0%
(Quality of evidence: II-2/III; Classification of recommendation: C) 
In young males, fatal cases of hepatosplenic T 
cell lymphoma have been reported in patients on 
combination infliximab and thiopurine, or thiopurine 
alone, but not in those on infliximab alone.32 
Therefore, the use of the combination therapy with 
biologics and thiopurine monotherapy should be 
appraised carefully in each patient, and the risks and 
benefits need to be discussed.
Statement 10: In Crohn’s disease patients who have 
lost response to a biologic and after exclusion of 
complications, a dose-intensification strategy (increase 
in dose or a decrease in dosing interval) or switching 
to a different biologic can be effective
Level of agreement: A-27%, B-60%, C-13%, D-0%, E-0% 
(Quality of evidence: II-1; Classification of recommendation: B)
About one third of patients treated with biologics lose 
responsiveness at 1 year. In cases of secondary loss 
of response, it is important to confirm active CD and 
exclude complications such as infections. Following 
that, initiation of a short course of corticosteroids, 
increase in dosage or reduction in the dosing interval 
of anti-TNFs, or switching to a different biologic can 
be considered.27 However, no controlled data or 
head-to-head comparisons are available to indicate 
which method is superior. In the opinion of panel 
members, dosage increase or reduction of the 
dosing interval of current anti-TNF therapy should be 
attempted before switching to a different biologic.
Statement 11: Biologics are effective for inducing and 
maintaining remission in paediatric Crohn’s disease 
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patients with moderate-to-severe disease who are 
refractory to or intolerant of conventional therapy
Level of agreement: A-67%, B-27%, C-7%, D-0%, E-0% 
(Quality of evidence: I; Classification of recommendation: A)
Currently, first-line induction or remission therapy 
of CD continues to depend on steroids or exclusive 
enteral nutrition; the latter being associated with 
fewer side-effects, reversal of growth failure and 
mucosal healing.33 Biologics are also effective in 
inducing and maintaining responses and remissions 
in paediatric CD. In the REACH (Randomized, 
multicenter, open-label study to Evaluate the safety 
and efficacy of Anti-TNF alpha Chimeric monoclonal 
antibody in pediatric subjects with moderate to 
severe Crohn’s disease) trial, 88% of children with 
moderate-to-severe disease responded to infliximab 
and 59% achieved clinical remission at week 10.34 
At 3 years, approximately 80% of patients had no-
to-mild disease activity, and patients with ≥1-year 
delay in bone age at baseline showed improvement 
in height.35 For adalimumab, a prospective study 
showed a 91% response rate and 65% remission rate 
at 1 year.36 In a retrospective study, 70% and 42% of 
children with moderate-to-severe CD previously 
treated with infliximab achieved a clinical response 
and steroid-free remission on adalimumab at 1 year, 
respectively.37 
Screening and contra-indications of biologics
Statement 12: Biologics may not be beneficial in 
patients with fibrostenotic Crohn’s disease
Level of agreement: A-27%, B-73%, C-0%, D-0%, E-0% 
(Quality of evidence: II-1; Classification of recommendation: B)
According to the London Position Statement, patients 
with fibrostenotic CD without objective evidence of 
active inflammation (based on elevated C-reactive 
protein levels, endoscopy, or radiographic assessment) 
rarely benefit from biological therapy.32 Strictures are 
not an absolute contra-indication to anti-TNF therapy, 
but if there is evidence of pre-stenotic dilatation, the 
fibrotic component is less likely to be reversed by 
medical therapy and for most patients endoscopic 
dilatation, stricturoplasty, or stricture resection may 
be deemed necessary.32
Statement 13: Patients with active infection should 
be treated (eg abscess should be drained) before 
considering the use of biologics
Level of agreement: A-67%, B-27%, C-7%, D-0%, E-0% 
(Quality of evidence: III; Classification of recommendation: C)
For obvious reasons, patients with an active infection 
should not receive biological therapy until it is under 
control.32 Any abscess needs to be drained. Also, 
patients who have received live vaccines should not 
receive biological therapy for at least 3 months.32
Statement 14.a: All inflammatory bowel disease 
patients should be screened for hepatitis B virus status 
prior to initiation of biologics
Level of agreement: A-87%, B-13%, C-0%, D-0%, E-0% 
(Quality of evidence: II-2; Classification of recommendation: B)
Patients with IBD undergoing anti-TNF treatment 
have an increased risk of hepatitis B virus (HBV) 
reactivation. Liver dysfunction is more frequent in 
HBV carriers treated with immunosuppressive agents; 
36% of whom suffer from liver failure.38 Therefore, 
HBV screening (checking hepatitis B surface antigen 
[HBsAg] and anti-HBs antibody) is necessary at the 
time of diagnosing CD, particularly in Hong Kong. 
Close surveillance of liver function is necessary 
prior to biological therapy,39 and monitoring should 
continue for 6 to 9 months after cessation of anti-TNF 
therapy. Levels of HBV-DNA should be monitored in 
patients found to be HBsAg-positive. 
Statement 14.b: Initiation of antiviral therapy should 
be individualised
Level of agreement: A-40%, B-60%, C-0%, D-0%, E-0% 
(Quality of evidence: III; Classification of recommendation: C)
According to the European Crohn’s and Colitis 
Organisation recommendations on HBV, to avoid a 
hepatitis B flare, any IBD patients who are HBV carriers 
should receive pre-emptive therapy with antiviral 
agents prior to receiving immunomodulator therapy, 
regardless of the degree of viraemia.40 In terms of 
optimal strategy, there is no evidence on whether 
non-selective pre-emptive antiviral prophylaxis, 
selective antiviral prophylaxis in high-risk groups, or 
close surveillance and early antiviral treatment for 
progressive viraemia is the best treatment. Antiviral 
therapy for HBV should therefore be individualised. 
For hepatitis C virus (HCV), there is little evidence that 
treatment with biologics interferes with HCV activity 
and routine prophylactic treatment is generally not 
recommended.41
Statement 15: Screening for tuberculosis by history, 
physical examination, chest X-ray, and tuberculin skin 
test is mandatory prior to the initiation of biologics. 
Biologics should be postponed and anti-tuberculosis 
chemoprophylaxis or treatment should be given to 
patients with latent or active tuberculosis
Level of agreement: A-73%, B-27%, C-0%, D-0%, E-0% 
(Quality of evidence: II-2; Classification of recommendation: B)
Anti-TNF therapy increases the risk of tuberculosis 
(TB) by about 4-fold, with a median onset at about 
12 weeks.42 Therefore, a thorough TB screening 
by history, physical examination, chest X-ray, and 
tuberculin skin testing should be performed 
prior to initiating therapy (Fig).42 Due to frequent 
false-negative tuberculin tests, the use of gamma 
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interferon-based assays may help to increase their 
sensitivity and specificity. High vigilance must 
be maintained for reactivation of TB in patients 
receiving anti-TNF therapy, and close monitoring 
of patients should continue for 6 to 9 months after 
cessation of biologics. Patients considered at high 
risk for latent TB should receive chemoprophylaxis 
(isoniazid alone for 6-9 months, rifampicin alone for 
4 months, or isoniazid and rifampicin for 3 months). 
Chemoprophylaxis should be given for at least 1 
month before starting anti-TNF therapy.42
Statement 16: Patients with a history of solid cancer 
or lymphoproliferative disease should not receive 
biologics if there are other options available
Level of agreement: A-7%, B-80%, C-13%, D-0%, E-0% 
(Quality of evidence: III; Classification of recommendation: C)
Although there are few convincing data on the 
risk of anti-TNF therapy in patients with a history 
of previous malignancy, the 2009 London Position 
Statement stated that such patients or those with 
prior lymphoproliferative disorder should not be 
treated with anti-TNF if other options exist.32 A 
recent literature review concluded that because of 
the potential for progression, anti-TNF therapy is an 
absolute contra-indication in patients who have had a 
solid cancer or haematological malignancy diagnosed 
within the past 5 years.39 On the other hand, cancers 
diagnosed more than 5 years earlier and considered 
cured after treatment may be regarded as having a 
relative contra-indication only.39 
Monitoring after use of biologics
Statement 17: Patients should be closely monitored for 
infective complications after treatment with biologics, 
in particular mycobacterial and other opportunistic 
infections. Close liaison with infectious disease 
specialists is recommended
Level of agreement: A-33%, B-60%, C-7%, D-0%, E-0% 
(Quality of evidence: III; Classification of recommendation: B)
Biologics have been reported to increase the risk of 
mycobacterial and other opportunistic infections such 
as listeriosis, nocardiosis, and invasive aspergillosis.43 
In patients with any suspected infection, close liaison 
with infectious disease specialists is recommended 
after the initiation of treatment with biologics.
Statement 18: Patients should be observed for rare but 
severe cardiac and neurological complications. Prompt 
discontinuation of biologics is essential if heart failure 
develops or demyelinating disease is suspected
Level of agreement: A-40%, B-60%, C-0%, D-0%, E-0% 
(Quality of evidence: II-3/III; Classification of recommendation: C)
There is a lack of controlled trials in assessing the risk 
of anti-TNFs in patients with heart failure, but they are 
contra-indicated in patients with class III-IV congestive 
heart failure due to sporadic case reports showing an 
increased risk of death.44 New onset or exacerbation 
of central nervous system demyelinating disorders 
has also been reported with the use of anti-TNFs.44 A 
high level of vigilance must therefore be maintained 
for patients on anti-TNF therapy with pre-existing or 
recent heart failure or a demyelinating disorder; such 
therapy should cease immediately if any exacerbation 
is suspected.
Statement 19: High vigilance should be exercised 
regarding the risk of hepatosplenic T-cell lymphoma 
FIG.  Recommended strategy for tuberculosis screening and treatment in patients with inflammatory bowel disease
Adapted from Papa et al39
Detailed history (risk factors) and physical examination
Patients on immunosuppressive therapy?
Tuberculin skin test
Start infliximab
Positive Negative Abnormal Negative NegativePositive
Chemoprophylaxis
Chest X-ray
No Yes
Interferon-γ release assays
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in young patients receiving concomitant thiopurine 
therapy and anti–tumour necrosis factor agents
Level of agreement: A-67%, B-33%, C-0%, D-0%, E-0% 
(Quality of evidence: II-2; Classification of recommendation: B)
Although there has been no convincing data proving 
the risk of cancer in IBD patients undergoing anti-
TNF treatment, hepatosplenic T-cell lymphoma 
(a rare form of non-Hodgkin’s lymphoma) was 
reportedly associated with the concomitant use of 
anti-TNFs and azathioprine.43 A link between anti-
TNFs and lymphomas or other malignancies cannot 
be completely excluded.
Conclusions
Although anti-TNFs have been available for more than 
a decade, their use in Hong Kong remains limited and 
local clinicians may still be unfamiliar with them. This 
is the first consensus statement on the appropriate 
use of biologics in the treatment of IBD in Hong 
Kong. We have attempted to address a variety of 
topics including the target patients and appropriate 
use of biologics, contra-indications and precautions 
with the use of biologics, and issues related to patient 
monitoring. The current paper also summarises the 
recent clinical efficacy and safety data of different anti-
TNFs for treating various forms of CD and UC, which 
provides supporting evidence for local clinicians to 
treat their patients with biologics. Recommendations 
on timing of initiation of biologics, dosing schedules, 
and drug combinations have also been indicated 
to promote their proper use to achieve optimal 
outcomes. However, due to the paucity of local or 
even any Asian data, many of these recommendations 
are based on western published data. It is possible 
that treatment responses to biologics may vary in 
local Chinese IBD patients, due to differences in drug 
pharmacokinetics and phenotypic and genotypic 
characteristics of the disease between Asian and 
western patients. Hence, more local experience and 
data are necessary to provide a more evidence-based 
local guideline on the treatment for our patients. 
While agreement exists pertaining to the messages 
conveyed in the consensus statements, it is important 
to recognise that the final decision on the therapeutic 
approach needs to be tailored to fit individual patient 
needs. 
 These consensus statements aim to provide 
local clinical experts with information about the 
benefits and risks associated with biological therapies 
for patients with IBD, and serve as a reference for 
their appropriate use. 
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